MicroPort Scientific (853) H1 2025 earnings summary

Executive summary

• Revenue for 1H25 was US$547.5 million, down 2.2% year-over-year, reflecting industry headwinds and delayed procurement cycles.

• Net loss narrowed by 65.9% to US$36.4 million, driven by cost controls, divestment of non-core businesses, and operational efficiency.

• EBITDA more than doubled year-over-year to US$127.8 million, reflecting improved operational efficiency.

• Overseas business revenue surged 57.3% year-over-year, highlighting global expansion success.

• Adjusted (non-HKFRS) profit for the period was US$1.2 million, compared to a loss of US$64.1 million in the prior year.

Financial highlights

• Gross margin declined to 56.4% from 59.2% year-over-year due to price reductions and sales mix changes.

• R&D costs fell 37.3% to US$72.1 million, with the R&D cost ratio dropping from 20.6% to 13.2%.

• Operating expenses fell 14.5% to US$303.5 million; distribution and administrative expenses decreased by 4.9% and 1.2%.

• Other net income rose to US$54.8 million, mainly from FX gains and government grants.

• Finance costs increased 21.8% to US$59.0 million, mainly due to higher interest expenses.

Outlook and guidance

• Management remains confident in long-term growth, focusing on innovation, global expansion, and cost control.

• Strategic restructuring of cardiac rhythm management and structural heart disease businesses is underway to build an integrated cardiovascular platform.

• Continued emphasis on risk management, lean operations, and internationalization to navigate market uncertainties.